Real-World Applications: How Scientists Are Using Isohelix Products to Advance Cancer Research

Genomic research is at the heart of efforts to understand, detect and treat cancer. From identifying hereditary risk variants to characterizing tumor biology, the quality of genetic  analysis depends on the quality of nucleic acid samples analyzed. 

Whether samples are collected in the lab or remotely, extracted nucleic acids must be able  to support sensitive downstream applications such as genome-wide association studies  (GWAS), next-generation sequencing (NGS) and epigenetic analyses. 

Isohelix sample collection, stabilization and extraction products have been designed to  meet this challenge. Combining non-toxic, guanidinium-free chemistry with high-yield  collection formats and a room-temperature storage capability of up to 60 months, Isohelix  products are trusted by researchers around the world for their sample collection needs. 

In this article, we present four studies where Isohelix products have been used for different  aspects of cancer research: 

• Identifying Breast Cancer Risk in Younger Women: The BCAN-RAY Study

• Expanding Access to BRCA Testing: The BRCA-DIRECT Study 

• Oral Microbiome Disruption as a Marker of Oral Cancer 

• Genomic Biomarkers of Chemoradiation Response in Cervical Cancer

Identifying Breast Cancer Risk in Younger Women: The BCAN-RAY Study 

The Breast Cancer Risk Assessment in Younger Women BCAN-RAY study began in May  2023. This ongoing study aims to evaluate a comprehensive breast cancer risk assessment  strategy among a diverse ethnic and socioeconomic population of women aged 30–39  years, without a strong family history of breast cancer. 

The study recruited 250 women previously diagnosed with breast cancer alongside 750  control participants aged 30–39 years. None of the participants had a strong family history  of the disease. 

Control participants complete questionnaires about breast cancer risk factors, undergo  low-dose mammograms, and donate a saliva sample which are collected using Isohelix  GeneFix Saliva Collection Kits. Saliva samples are used to analyze the genetic makeup of  all participants and identify those at higher risk using a tool called a polygenic risk score,  which is a powerful predictor of breast cancer risk. 

Expanding Access to BRCA Testing: The BRCA-DIRECT Study 

A second breast cancer study, the BRCA-DIRECT study aims to provide an easy way for  patients with breast cancer to access genetic testing within the NHS, and examines the  feasibility, safety, and acceptability of a digital information model. 

The study investigates the BRCA1, BRCA2, and PALB2 genes, which are associated with  hereditary breast cancer. The identification of a pathogenic variant in one of these genes  can have health implications for patients and their relatives. 

Participants provide a saliva or blood sample and access a digital platform. Family history  details are collected, and information gathered about the donor’s general knowledge of  BRCA testing. Participants were asked about their anxiety levels at different points in the  process. Half of all those who took part saw digital information, and half booked a standard  appointment with genetic counsellors. 

Participants are then randomized to receive their results digitally or by booking a telephone  appointment with a genetic counsellor. Everyone who has a positive result is then referred  to their local clinical genetics team. If the digital pathway is successful, the concept could  be expanded to other cancers and hospitals.

Oral Microbiome Disruption as a Marker of Oral Cancer 

The oral microbiome is increasingly recognized as a potential biomarker for diseases  including oral cancer. In the publication, “Differences in the bacteriome of swab, saliva,  and tissue biopsies in oral cancer” (Gopinath et al 2021), researchers characterized the  bacteriome of saliva, swab, and tissue biopsy samples. 

Isohelix sample collection products were used to collect samples, which were analyzed using MiSeq sequencing to compare the bacterial communities of oral cancer patients to  those of normal healthy controls in Indian cohorts. The study found significant variation in  the bacterial flora in whole mouth fluid (WMF), tumor tissue and the tumor surface. The  oral bacteriome of patients with oral cancer differed from that of healthy mouths, and  these variations were not restricted to oral cancer tissues. 

The ability to detect cancer-associated microbiome signatures using saliva rather than  tissue biopsy has obvious clinical potential. The non-invasive longitudinal monitoring of  microbiome composition in high-risk patients could offer an early warning system for  malignant progression without the need for repeated invasive procedures. 

Genomic Biomarkers of Chemoradiation Response in Cervical Cancer 

In the final featured study, by Nolasco et al (2025), genomic changes were investigated as  biomarkers of chemoradiation therapy response in locally advanced cervical cancer. 

Locally advanced cervical cancer is typically treated with concurrent chemoradiation  therapy (CRT), but clinical responses vary considerably between patients. Identifying  genomic biomarkers that can predict or monitor treatment response would enable  clinicians to personalize care and potentially intervene earlier in patients who are not  responding as expected. 

Using Isohelix sample collection and processing technology to obtain high-integrity DNA  from study participants, the investigators evaluated whether genomic alterations  detectable before and during treatment could serve as indicators of response or resistance  to chemoradiation therapy. The study found that genomic changes can be observed before  and after CRT in cervical cancer, but further validation is needed to determine their clinical  utility in guiding CRT outcomes. 

This study exemplifies a rapidly growing application area for non-invasive DNA collection:  serial sampling across the course of treatment. Isohelix GeneFix™ devices stabilize DNA  immediately upon collection and require no cold storage, so the same participant can  donate samples at multiple time points, in the clinic, at home, or at a local collection point, 

without compromising sample quality. This longitudinal flexibility is increasingly important  as cancer research moves toward real-time monitoring of treatment response. 

Why Researchers Choose Isohelix for Cancer Genomics 

As cancer genomics continues to evolve towards larger cohorts, more sensitive assays,  longitudinal monitoring, and increasingly personalized treatment decisions, the need for  reliable, accessible, and scalable sample collection solutions continues to grow. 

Across each of these studies, Isohelix products provided reliable, high-quality DNA and  RNA samples enabling cancer researchers to generate meaningful results. 

Several features make Isohelix particularly well-suited to cancer genomics research: 

• Non-invasive collection: Saliva and buccal swab sampling removes barriers to  participant recruitment, particularly for community-based studies and those  involving patients who may find repeated venepuncture difficult or distressing. 

• Room-temperature stability: GeneFix™ products stabilize DNA at room temperature  for up to 60 months, eliminating cold chain requirements and making postal sample  collection straightforward 

• Guanidinium-free chemistry: All GeneFix™ stabilization buffers are non-toxic and  guanidinium-free, making them safe for participants to handle at home and  compliant with standard postal regulations. 

• High-yield, high-purity DNA: Isohelix extraction kits are optimized to work with  GeneFix™ collectors, delivering DNA of sufficient purity and integrity for demanding  applications including GWAS, whole-genome sequencing and microbiome analysis. • Scalability: Isohelix products are available in formats suitable for studies ranging  from small, single-site investigations to large-scale biobanking programs enrolling  thousands of participants.

AutoGen offers a wide range of high-quality, cost-effective Isohelix solutions for DNA and
RNA collection from saliva and the microbiome. These high-quality collectors make it easy
to collect high-yielding samples for genomic applications. Contact our team to discuss
your sample collection requirements.